IP Library › Granted Patent US 11,401,541
Granted Patent B2
US 11,401,541 · App. 17/070,385 · Granted Aug 2, 2022

Solid form of (-)-Ambrox formed by a bioconversion of homofarnesol in the presence of a biocatalyst

Inventors: Ghislain Sanhaji (Warmeriville, FR); Alix Rousseaux (Verzenay, FR); Sandrine Noel (Warmeriville, FR); Eric Eichhorn (Zurich, CH)
Assignee: Givaudan S.A.
C12P17/04A61Q13/00C07D307/92C07B2200/07C07B2200/13C12Y504/99017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,401,541
App. No.
17/070,385
Granted
Aug 2, 2022
Kind
B2
Abstract

A solid form of (−)-Ambrox formed by a bioconversion process.

Claims (18)

1. A solid form of the compound according to the formula (I)

wherein, said solid form:

exhibits an x-ray diffraction pattern having at least one of the following peaks at diffraction angles 2 theta of 15.6, 16.2, 16.7, 17.0, 17.4, 18.3+/−0.2°;

it comprises elongate crystals having an average diameter of at least 10 to 400 microns measured by laser granulometry;

it comprises elongate crystals having a length along their longest dimension of greater than 100 micron; and/or

it has an value of 90 or more; an value of less than 1 and greater the −1; and a value, which is less than 8, wherein , and values represent CIELAB chromaticity coordinates.

2. The solid form according to claim 1 , wherein the x-ray diffraction pattern exhibits all of the following peaks at diffraction angles 2 theta of 15.6, 16.2, 16.7, 17.0, 17.4 and 18.3+/−0.2°.

3. The solid form according to claim 2 , characterized by an x-ray diffraction pattern as depicted in FIG. 1 .

4. The solid form according to claim 1 , which is a product of a bioconversion process.

5. The solid form according to claim 4 , wherein the bioconversion process is an enzyme-catalyzed cyclization of homofarnesol comprising a mixture of 7E,3E and 7E,3Z geometric isomers of homofarnesol, wherein the reaction is carried out in the presence of a biocatalyst.

6. The solid form according to claim 5 , wherein the biocatalyst is a recombinant microorganism expressing the gene coding the enzyme, or an isolated enzyme, or an immobilized enzyme.

7. The solid form according to claim 6 , wherein the enzyme is a wild-type squalene hopene cyclase, or a variant of the wild-type squalene hopene cyclase.

8. The solid form according to claim 1 , having an value of 90 or more; an value of less than 1 and greater than −1; and a value, which is less than 8, wherein , and represent Cielab chromaticity coordinates.

9. A perfume composition comprising the solid form of (−)-Ambrox as defined in claim 1 , dissolved or dispersed in said composition.

10. A household care, personal care, laundry care or air care composition comprising the perfume composition according to claim 9 .

11. The solid form according to claim 1 , wherein it comprises elongate crystals having an average diameter of at least 10 to 400 microns measured by laser granulometry.

12. The solid form according to claim 1 , wherein it comprises elongate crystals having a length along their longest dimension of greater than 100 micron.

13. The solid form according to claim 6 , wherein the cyclization reaction is carried out in the presence of an SHC biocatalyst capable of bioconverting homofarnesol to (−)-Ambrox.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2020
From: SANHAJI, GHISLAIN; ROUSSEAUX, ALIX; NOEL, SANDRINE; EICHHORN, ERIC
To: GIVAUDAN SA
Reel/Frame 054053/0177 →
Priority Claims (3)
WO PCT/EP2016/058987 · Apr 22, 2016 · international
WO PCT/EP2016/058997 · Apr 22, 2016 · international
GB 1618090 · Oct 26, 2016 · national
Continuity (2)
Continuation 16095444
Related Publication 20210040521A1 · Feb 11, 2021